このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase II Study of Ivonescimab Combined With Iza-bren in Patients With Advanced Non-Small Cell Lung Cancer. (PEGASUS-Lung)

A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Ivonescimab Combined With Iza-bren Brengitecan in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Resistant to Third-Generation EGFR-TKIs

This is a prospective, multicenter, open-label, single-arm phase II clinical study evaluating the efficacy and safety of ivonescimab (a PD-1/VEGF bispecific antibody) combined with Iza-bren (BL-B01D1; izalontamab brengitecan, an EGFR×HER3 bispecific antibody-drug conjugate) in patients aged ≥18 years with histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations (exon 19 deletion or L858R) who have imaging-confirmed disease progression during or after prior third-generation EGFR-TKI therapy. A total of 43 subjects will be enrolled at 3 centers. The primary endpoint is progression-free survival (PFS). Other efficacy endpoints include ORR, confirmed ORR, DCR, DoR, OS, 6- and 12-month PFS rates, and 12- and 24-month OS rates. Safety and tolerability will be assessed, and exploratory analyses will evaluate immune markers, HER3 expression, and EGFR resistance molecular subtypes in relation to clinical efficacy. Treatment is given every 3 weeks: ivonescimab 20 mg/kg intravenously on Day 1; Iza-bren 2.5 mg/kg intravenously on Days 1 and 8. Ivonescimab is infused first, followed by Iza-bren after an interval of ≥30 minutes. Treatment continues until disease progression, intolerable toxicity, initiation of new anti-cancer therapy, death, withdrawal of consent, or a maximum of 24 months of treatment.

調査の概要

状態

まだ募集していません

詳細な説明

Study Design Prospective, multicenter, single-arm phase II study Objectives

Primary objective:

To evaluate the efficacy and safety of ivonescimab combined with Iza-bren in patients with EGFR-sensitizing mutation-positive advanced non-squamous NSCLC after progression on third-generation EGFR-TKIs.

Secondary objectives:

  1. To explore the correlation of baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy;
  2. To analyze efficacy differences in the baseline brain metastasis subgroup and among different EGFR mutation subtypes (19del/L858R);
  3. To explore the association of tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) with PFS and OS outcomes.

Endpoints

  1. Progression-free survival (PFS), objective response rate (ORR), confirmed objective response rate (cORR), and overall survival (OS); to calculate 6-month and 12-month PFS rates and 12-month and 24-month OS rates;
  2. To evaluate the overall safety and tolerability of the combination regimen, and to describe the type, incidence, severity (CTCAE 6.0), duration, management measures, and outcomes of treatment-related adverse events (TRAEs).

Study Population Pathologically confirmed non-squamous NSCLC harboring EGFR-sensitizing mutations, with imaging-confirmed progression after third-generation EGFR-TKI therapy (age ≥18 years, any sex).

Inclusion/Exclusion Criteria

Inclusion criteria (all must be met):

  1. Voluntary written informed consent and ability to comply with study procedures; age ≥18 years, any sex.

  2. Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC (AJCC 8th edition).

  3. EGFR-sensitizing mutation (exon 19 deletion or L858R) confirmed by tissue, cytology, or plasma ctDNA; concomitant resistance mutations such as T790M, C797S, and 861Q are allowed.

  4. Prior standard treatment with a third-generation EGFR-TKI (osimertinib, almonertinib, furmonertinib, etc.), with imaging-confirmed disease progression during or after treatment.

  5. ECOG performance status 0 or 1; expected survival ≥3 months.

  6. At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm; lymph node short diameter ≥15 mm).

  7. Without transfusion or use of colony-stimulating factors, thrombopoietin, or any cell growth factor within 14 days before screening tests, organ function must meet the following criteria:

    • Hematology: ANC ≥1.5×10⁹/L; PLT ≥75×10⁹/L; Hb ≥90 g/L;
    • Liver function: AST/ALT ≤2.5×ULN (≤5×ULN in patients with liver metastases); total bilirubin ≤1.5×ULN;
    • Renal function: creatinine ≤1.5×ULN; urine protein ≤2+ or ≤1000 mg/24 h;
    • Coagulation: INR and APTT ≤1.5×ULN.
  8. Toxicities from prior anti-cancer therapy have recovered to ≤ grade 1 per NCI-CTCAE v6.0 (except alopecia, fatigue, pigmentation, hypothyroidism stable on hormone replacement, grade 2 peripheral neuropathy after chemotherapy, and other exceptions specified in the inclusion criteria).

  9. Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test is negative at screening for women of childbearing potential.

Exclusion criteria (any one excludes):

  1. Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
  2. Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
  3. Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
  4. Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
  5. Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
  6. Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
  7. Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
  8. QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
  9. Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
  10. Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
  11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  12. Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
  13. Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
  14. Pregnant or lactating women.
  15. Concurrent participation in other interventional anti-cancer clinical trials.
  16. Investigator considers the patient unsuitable for participation in this study. Randomization and Intervention Plan Ivonescimab: 20 mg/kg, intravenous infusion on Day 1 of each cycle; first infusion time 60±10 minutes; for patients unable to tolerate a 60-minute infusion, the infusion time may be extended up to 120 minutes; if no infusion reaction occurs, subsequent cycles may be shortened to 30-60 minutes.

Iza-bren: 2.5 mg/kg, intravenous drip on Days 1 and 8 of each cycle; first infusion time ≥120 minutes; after tolerance, it may be adjusted to 60-120 minutes.

Follow-up Plan Treatment-period follow-up: once before each treatment cycle to assess safety and compliance; efficacy follow-up with imaging every 6 weeks.

End-of-treatment (EOT) visit: 28±7 days after the last dose; complete physical examination, laboratory tests, imaging assessment (conditional), and AE follow-up.

Survival follow-up: every 90±7 days after EOT, via outpatient visit, telephone, WeChat, etc.; record survival status, subsequent anti-cancer treatment, and living status.

Sample Size Calculation A total of 43 subjects are planned. Based on the one-sample log-rank method: the expected number of events under the alternative hypothesis is 32.26; with 38 subjects enrolled, the asymptotic power can reach 80.78%, meeting the prespecified power requirement; considering a 10% dropout rate, the final sample size is 43.

研究の種類

介入

入学 (推定)

43

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Voluntary written informed consent, age ≥18 years, any sex.

  2. Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC (AJCC 8th edition).

  3. Confirmed EGFR-sensitizing mutation (Exon 19 deletion or L858R) in tissue, cytology, or plasma ctDNA. Concomitant resistance mutations (e.g., T790M, C797S, 861Q) are allowed.

  4. Prior standard treatment with a third-generation EGFR-TKI (e.g., osimertinib, almonertinib, furmonertinib), with imaging-confirmed disease progression during or after treatment.

  5. ECOG performance status of 0 or 1; expected survival ≥3 months.

  6. At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm, or lymph node short diameter ≥15 mm).

  7. Adequate organ function (without transfusion or growth factors within 14 days prior to screening):

    Hematology: ANC ≥1.5×10^9/L; PLT ≥75×10^9/L; Hb ≥90 g/L. Liver: AST/ALT ≤2.5×ULN (≤5×ULN for liver metastases); Total bilirubin ≤1.5×ULN.

    Renal: Creatinine ≤1.5×ULN; Urine protein ≤2+ or ≤1000 mg/24h. Coagulation: INR and APTT ≤1.5×ULN.

  8. Prior treatment-related toxicities have recovered to ≤ Grade 1 per NCI-CTCAE v6.0 (except for alopecia, fatigue, pigmentation, stable hypothyroidism on hormone replacement, or grade 2 peripheral neuropathy from chemotherapy).

  9. Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test must be negative for women of childbearing potential at screening.

Exclusion Criteria:

  1. Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
  2. Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
  3. Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
  4. Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
  5. Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
  6. Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
  7. Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
  8. QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
  9. Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
  10. Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
  11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  12. Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
  13. Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
  14. Pregnant or lactating women.
  15. Concurrent participation in other interventional anti-cancer clinical trials.
  16. Investigator considers the patient unsuitable for participation in this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ivonescimab combined with Izabren

Patients receive ivonescimab (20 mg/kg IV on Day 1) and Iza-bren (2.5 mg/kg IV on Days 1 and 8) every 3 weeks (21-day cycle). Treatment continues until disease progression, unacceptable toxicity, or up to 24 months.

20 mg/kg, intravenous infusion on Day 1 of each 21-day cycle.

他の名前:
  • AK112

2.5 mg/kg, intravenous drip on Days 1 and 8 of each 21-day cycle.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-Free Survival (PFS)
時間枠:From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).

PFS is defined as the time from the first dose of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first. Participants who are alive and progression-free at the time of analysis will be censored at the last adequate tumor assessment.

From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR)
時間枠:Up to approximately 24 months.

The proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Confirmed Objective Response Rate (cORR)
時間枠:Up to approximately 24 months.

The proportion of participants with a confirmed CR or PR (confirmed by repeat imaging at least 4 weeks later), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Disease Control Rate (DCR)
時間枠:Up to approximately 24 months.

The proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by investigators according to RECIST v1.1.

Up to approximately 24 months.
Duration of Response (DoR)
時間枠:From first documented response to disease progression or death (up to approximately 24 months).

The time from the first documentation of CR or PR to the first documentation of disease progression or death from any cause, whichever occurs first.

From first documented response to disease progression or death (up to approximately 24 months).
Overall Survival (OS)
時間枠:From the first dose of study treatment to death from any cause (up to approximately 42 months).

The time from the first dose of study treatment to death from any cause.

From the first dose of study treatment to death from any cause (up to approximately 42 months).
6-month and 12-month PFS Rates
時間枠:At 6, 12 months after the first dose.

The probability of participants remaining progression-free at specific time points, estimated using the Kaplan-Meier method.

At 6, 12 months after the first dose.
12-month and 24-month OS Rates
時間枠:At 12 and 24 months after the first dose.

The probability of participants remaining alive at specific time points, estimated using the Kaplan-Meier method.

At 12 and 24 months after the first dose.
Safety and Tolerability (Incidence of Treatment-Related Adverse Events)
時間枠:From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).

The incidence, severity (graded by NCI-CTCAE v6.0), duration, and management of treatment-related adverse events (TRAEs).

From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).

その他の成果指標

結果測定
メジャーの説明
時間枠
Correlation of Biomarkers with Clinical Efficacy
時間枠:Baseline, during treatment, and up to approximately 42 months.

To explore the correlation between baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy (e.g., ORR, PFS).

Baseline, during treatment, and up to approximately 42 months.
Efficacy Analysis in Specific Subgroups
時間枠:Up to approximately 42 months.

To analyze the differences in efficacy (such as ORR and PFS) among patients with baseline brain metastases and different EGFR mutation subtypes (exon 19 deletion vs. L858R).

Up to approximately 42 months.
Association of Immune Markers with Survival Outcomes
時間枠:Up to approximately 42 months.

To explore the association between tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) and survival outcomes (PFS and OS).

Up to approximately 42 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2030年6月1日

研究の完了 (推定)

2030年6月1日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IIT-2026-10-22

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する